ADMA Biologics stock slides nearly 4% as biotech weakens in thin year-end trade
ADMA Biologics shares dropped 3.7% to $18.40 Tuesday, outpacing declines in broader biotech indexes during thin year-end trading. CEO Adam Grossman sold 21,000 shares at $19.79 on Dec. 15 under a pre-set plan. ADMA last reported third-quarter revenue of $134.2 million and raised its 2025 outlook to at least $510 million. The next earnings report is expected in early March.
